FDA Approves Inqovi for Acute Myeloid Leukemia

FRIDAY, May 22, 2026 (HealthDay News) -- The U.S. Food and Drug Administration has approved Inqovi (decitabine and cedazuridine) plus venetoclax for the treatment of adults with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older or who are ineligible for intensive induction chemotherapy.The combination of Inqovi plus venetoclax is the first and only oral hypomethylating regimen approved for this population, offering an alternative to parenteral hypomethylating agent-based regimens that require frequent clinic visits.The approval was based on results from the phase 2 ASCERTAIN-V study, which showed that the combination treatment resulted in 42 patients achieving a complete remission (CR; 41.6 percent), with a median time to CR of two months. The median duration of CR was not reached. Serious adverse reactions occurred in 82 percent of patients who received the combination treatment, including serious adverse reactions of febrile neutropenia (31 percent), sepsis (22 percent), pneumonia (15 percent), bacterial or viral infection (10 percent), hemorrhage (9 percent), and dyspnea (6 percent). Fatal adverse reactions occurred in 8 percent of patients."This approval marks an important step forward in expanding how treatment can be delivered for this patient population, offering an all‑oral option that can potentially reduce the overall treatment burden associated with receiving treatment in hospitals or infusion centers," Harold Keer, M.D., Ph.D., the chief medical officer at Taiho Oncology, said in a statement. "We believe this approach has the potential to make a meaningful impact for patients and caregivers."Approval of Inqovi was granted to Taiho Oncology.More Information.Sign up for our weekly HealthDay newsletter

FDA Approves Inqovi for Acute Myeloid Leukemia

Related Stories

FDA Approves Enhertu as Neoadjuvant, Adjuvant Treatment for Breast Cancer

Many Patients With Vitiligo Do Not Receive Treatment

Most First-Time Psych Hospitalizations Followed by Readmission or Long-Term Treatment

ESCMID: Treatment Failure Does Not Differ Between Amoxicillin, Amoxicillin-Clavulanate for Acute Sinusitis